Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial

Official title:

A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00012181
• Other study ID #: NCI-2012-01854
• Secondary ID: ADVL0017CCG-AO97
• Status: Completed
• Phase: Phase 1
• First received: March 3, 2001
• Last updated: July 1, 2013
• Start date: April 2001

Study information

• Verified date: July 2013
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid tumors or lymphoma.

Description:

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of flavopiridol in children with relapsed or refractory solid tumors or lymphomas.

II. Determine the toxic effects and pharmacokinetics of this drug in these patients.

III. Determine the antitumor activity of this drug in these patients.

OUTLINE: This is a dose-escalation, multicenter study.

Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3 to 6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients are followed every 6 months.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 18 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. primary completion date: January 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• Histologically confirmed relapsed or refractory solid tumor or lymphoma including:

• Neuroblastoma

• Osteosarcoma

• Ewing's sarcoma

• Rhabdomyosarcoma

• Wilms tumor

• CNS tumors

• Histological verification not required for brainstem tumors

• No acute leukemia

• Not eligible for higher priority COG phase I/II study

• Performance status - Karnofsky 50-100% (over age 10)

• Performance status - Lansky 50-100% (age 10 and under)

• At least 2 months

• Absolute neutrophil count at least 1,000/mm^3

• Platelet count at least 75,000/mm^3 (transfusion independent)

• Hemoglobin at least 8.0 g/dL (transfusion allowed)

• No granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow involvement

• Bilirubin no greater than 1.5 times normal

• SGPT no greater than 5 times normal

• Albumin at least 2 g/dL

• Creatinine no greater than 1.5 times normal

• Creatinine clearance or radioisotope glomerular filtration rate at least lower limit of normal

• Shortening fraction at least 27% by echocardiogram

• Ejection fraction at least 50% by MUGA

• Stable neurologic deficits within the past 2 weeks for patients with CNS tumors

• CNS toxicity less than grade 2

• No active graft-versus-host disease

• No active uncontrolled infection or other serious medical condition

• No uncontrolled diabetes mellitus

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• At least 7 days since prior biologic therapy and recovered

• Prior bone marrow or stem cell transplantation allowed

• At least 6 months since prior allogeneic stem cell transplantation

• At least 1 week since prior growth factors

• No concurrent immunomodulating agents

• At least 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered

• No other concurrent chemotherapy

• Concurrent dexamethasone for CNS tumors allowed if on stable dose for at least 2 weeks prior to study

• Concurrent corticosteroids allowed only for increased intracranial pressure in patients with CNS tumors

• At least 2 weeks since prior local (small port) palliative radiotherapy

• At least 6 months since prior radiotherapy to 50% or more of the pelvis

• At least 6 months since prior craniospinal radiotherapy

• At least 6 weeks since other prior substantial bone marrow radiotherapy

• Recovered from prior radiotherapy

• No concurrent radiotherapy except localized palliative radiotherapy

• No concurrent anticonvulsants

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Astrocytoma
• Ependymoma
• Glioma
• Hodgkin Disease
• Kidney Neoplasms
• Lymphoma
• Lymphoma, Non-Hodgkin
• Medulloblastoma
• Neoplasms
• Neoplasms, Germ Cell and Embryonal
• Neuroblastoma
• Neuroectodermal Tumors
• Neuroectodermal Tumors, Primitive
• Neuroectodermal Tumors, Primitive, Peripheral
• Optic Nerve Glioma
• Osteosarcoma
• Recurrent Childhood Brain Stem Glioma
• Recurrent Childhood Cerebellar Astrocytoma
• Recurrent Childhood Cerebral Astrocytoma
• Recurrent Childhood Ependymoma
• Recurrent Childhood Large Cell Lymphoma
• Recurrent Childhood Liver Cancer
• Recurrent Childhood Lymphoblastic Lymphoma
• Recurrent Childhood Malignant Germ Cell Tumor
• Recurrent Childhood Medulloblastoma
• Recurrent Childhood Rhabdomyosarcoma
• Recurrent Childhood Small Noncleaved Cell Lymphoma
• Recurrent Childhood Soft Tissue Sarcoma
• Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
• Recurrent Childhood Visual Pathway and Hypothalamic Glioma
• Recurrent Childhood Visual Pathway Glioma
• Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
• Recurrent Neuroblastoma
• Recurrent Osteosarcoma
• Recurrent Retinoblastoma
• Recurrent Wilms Tumor and Other Childhood Kidney Tumors
• Recurrent/Refractory Childhood Hodgkin Lymphoma
• Retinoblastoma
• Rhabdomyosarcoma
• Sarcoma
• Sarcoma, Ewing
• Unspecified Childhood Solid Tumor, Protocol Specific
• Wilms Tumor

Intervention

Drug:
• alvocidib
Given IV

Other:
• pharmacological study
Correlative studies

Locations

Country	Name	City	State
United States	COG Phase I Consortium	Arcadia	California

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD defined as the dose at which fewer than one-third of patients experience DLT assessed using Common Toxicity Criteria version 2.0		Day 21	Yes